
Clinical TrialNov 20, 2026, 10:31 AM
PMV Pharma: Rezatapopt Shows 48% ORR in Ovarian Cancer; NDA Planned Q1 2027
AI Summary
PMV Pharmaceuticals, Inc. reported updated results from its Phase 2 PYNNACLE clinical trial of rezatapopt for TP53 Y220C-mutated advanced solid tumors. The trial showed a 48% overall response rate (ORR) with a 10.4-month median duration of response in platinum-resistant/refractory ovarian cancer patients. The company plans to submit a New Drug Application (NDA) for rezatapopt in the first quarter of 2027.
Key Highlights
- 48% overall response rate (ORR) in primary analysis population of 65 platinum-resistant/refractory ovarian cancer patients.
- 10.4-month median duration of response in the primary analysis population.
- 36% ORR across all cohorts in the overall population of 168 evaluable patients.
- 8.1-month median duration of response in the overall population.
- NDA submission for platinum-resistant/refractory ovarian cancer planned for Q1 2027.
- Data presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026).
Price Impact
More from PMVP